Inhibition of Mycobacterium tuberculosis, Mycobacterium bovis, and Mycobacterium avium by novel dideoxy nucleosides

Journal of Medicinal Chemistry

Volumn 50, Issue 19, 2007, Pages 4766-4774

  Rai, Dinesh ^a   Johar, Monika ^a   Srivastav, Naveen C ^a   Manning, Tracey ^a   Agrawal, B ^a   Kunimoto, Dennis Y ^a   Kumar, Rakesh ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 4 FLUORO 7 (2,3 DIDEOXY BETA DEXTRO GLYCEROPENTOFURANOSYL)PYRROLO[2,3 D]PYRIMIDINE; 2 AMINO 6 MERCAPTOETHYL 9 (2,3 DIDEOXY BETA DEXTRO GLYCEROPENTOFURANOSYL)PURINE; 2',3' DIDEOXY 3' FLUOROURIDINE; 2',3' DIDEOXYURIDINE DERIVATIVE; 5 BROMO 2',3' DIDEOXYCYTIDINE; 5 CHLORO 4 THIO 2',3' DIDEOXYURIDINE; 5 METHYL 2',3' DIDEOXYCYTIDINE; NUCLEOSIDE; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; DNA SYNTHESIS; DRUG CYTOTOXICITY; DRUG STRUCTURE; DRUG SYNTHESIS; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MULTIDRUG RESISTANCE; MYCOBACTERIUM AVIUM; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PREVALENCE; RNA SYNTHESIS; VERO CELL;

ADENOSINE; ALKYNES; ANIMALS; ANTI-BACTERIAL AGENTS; CELL LINE; CELL SURVIVAL; DIDEOXYNUCLEOSIDES; DRUG RESISTANCE, BACTERIAL; GUANOSINE; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM AVIUM; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; PURINE NUCLEOSIDES; STRUCTURE-ACTIVITY RELATIONSHIP; URIDINE;

EID: 34648816227     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm070391t     Document Type: Article

References (54)

1. (a) Shah, N. S.; Wright, A.; Bai, G. H.; Barrera, L.; Boulahbal, F.; Martín-Casabona, N.; Drobniewski, F.; Gilpin, C.; Havelková, M.; Lepe, R.; Lumb, R.; Metchock, B.; Portaels, F.; Filomena, M.; Rüsch-Gerdes, S.; Rodrigues, S.; et al. Worldwide Emergence of Extensively Drug-Resistant Tuberculosis. Emerging Infect. Dis. 2007, 13, 380-387.
2. (b) Rouhi, A. M. Tuberculosis: A Tough Adversary. Chem. Eng. News 1999, May 17, 52-69.
3. (c) Kling, J. Enlisting a Genome to Fight MDR-Tuberculosis. Modern Drug Discovery 1999, Jan/Feb, 32-45.
4. (d) Campos-Outcalt, D. Tuberculosis: Old Problem, New Concerns. J. Family Pract. 2003, 52, 792-798.
5. (e) Tomioka, H. Current Status of Some Antituberculosis Drugs and the Development of New Antituberculous Agents. Curr. Pharm. Des. 2006, 12, 4047-4070.
6. (a) Valadas, E.; Antunes, F. Tuberculosis a Re-emergent Disease. Eur. J. Radiol. 2005, 55, 154-157.
7. (b) HIV, Tuberculosis and Malaria; WHO Fact Sheet No. 104; World Health Organization Information Resource Center: Geneva, Switzerland, 2004.
8. (c) Grassi, C. Anti-Infectives: New Drugs for Tuberculosis. Expert Opin. Invest. Drugs 1997, 6, 1211-1226.
9. (a) Long, R.; Houston, S.; Hershfield, E. Canadian Tuberculosis Committee of the Centre for Infectious Disease Prevention and Control, Population and Public Health Branch, Health Canada. Recommendations for Screening and Prevention of Tuberculosis in Patients with HIV and for Screening for HIV in Patients with Tuberculosis and their Contacts. Can. Med. Assoc. J. 2003, 169, 789-791.
10. (b) Nguyen, D.; Proulx, J. F.; Westley, J.; Thibert, L.; Dery, S.; Behr, M. A. Tuberculosis in the Inuit Community of Quebec, Canada. Am. J. Respir. Crit. Care Med. 2003, 168, 1353-1357.
11. (a) Maher, D.; Raviglione, M. Global Epidemiology of Tuberculosis. Clin. Chest Med. 2005, 26, 168-182.
12. (b) Pilheu, J. A. Tuberculosis 2000: Problems and Solutions. Int. J. Tuberculosis Lung Dis. 1998, 2, 696-703.
13. (a) Global Tuberculosis Control: Surveillance, Planning, Financing; WHO Report 2004: World Health Organization: Geneva, Switzerland, 2004.
14. (b) Raviglione, M. C.; Snider, D. E.; Kochi, A. Global Epidemiology of Tuberculosis. Morbidity and Mortality of a Worldwide Epidemic. JAMA, J. Am. Med. Assoc. 1995, 273, 220-226.
15. (a) Schlesinger, N.; Lardizabal, A.; Rao, J.; McDonald, R. Tuberculosis of the Spine: Experience in an Inner City Hospital. J. Clin. Rheumatol. 2005, 11, 17-20.
16. (b) Willcox, P. A. Drug-Resistant Tuberculosis. Curr. Opin. Pulm. Med. 2000, 6, 198-202.
17. (c) Méndez, A. P.; Raviglione, M. C.; Laszlo, A.; Binkin, N.; Rieder, H. L.; Bustreo, F.; Cohn, D. L.; Lambregts-van Weezenbeek, C. S. B.; Kim, S. J.; Chaulet, P.; Nunn, P. Global Surveillance for Anti-Tuberculosis-Drug Resistance, 1994-1997. World Health Organization - International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N. Engl. J. Med. 1998, 338, 1641-1649.
18. (d) Inderlied, C. B.; Kemper, C. A.; Bermudez, L. E. The Mycobacterium avium Complex. Clin. Microbiol. Rev. 1993, 6, 266-310.
19. (e) Falkinham, J. O., III. Epidemiology of Infection by Nontuberculous Mycobacteria. Clin. Microbiol. Rev. 1996, 9, 177-215.
20. Peloquin, C. A.; Berning, S. E. Infections Caused by Mycobacterium tuberculosis. Ann. Pharmacother. 1994, 28, 72-84.
21. (a) Guerrin-Tran, E.; Thiolet, J. M.; Rousseau, C.; Henry, S.; Poirier, C.; Che, D.; Vinas, J. M.; Jarlier, V.; Robert, J. An Evaluation of Data Quality in a Network for Surveillance of Mycobacterium tuberculosis Resistance to Antituberculosis Drugs in Ile-de-France Region. Eur. J. Epidemiol. 2006, 21, 783-785.
22. (b) Murray, J. F. Tuberculosis and HIV Iinfection: A Global Perspective. Respiration 1998, 65, 335-342.
23. (c) Gordin, F. M.; Nelson, E. T.; Matts, J. P.; Cohn, D. L. J.; Benator, E. D.; Besch, C. L.; Crane, L. R.; Sampson, J. H.; Bragg, P. S.; El-Sadr, W. The Impact of HIV Infection on Drug-Resistant Tuberculosis. Am. J. Respir. Crit. Care Med. 1996, 154, 1478-1483.
24. (d) Moss, A. R.; Alland, D.; Telzak, E.; Hewlett, D., Jr.; Sharp, V.; Chiliade, P.; LaBombardi, V.; Kabus, D.; Hanna, B.; Palumbo, L.; Brudney, K.; Weltman, A.; Stoeckle, K.; Chirgwin, K.; Simberkoff, M.; Moghazeh, S.; Eisner, W.; Lutfey, M.; Kreiswirth, B. A City-Wide Outbreak of a Multiple-Drug-Resistant Strain of Mycobacterium tuberculosis in New York. Int. J. Tuberculosis Lung. Dis. 1997, 1, 115-121.
25. (e) National Survey of Tuberculosis in England and Wales. Communicable Dis. Rep. Wkly. 1998, 8, 209-212.
26. (a) Cohen, J. Extensively Drug-Resistant TB Gets Foothold in South Africa. Science 2006, 313, 1554.
27. (b) Wright, A. Emergence of Mycobacterium tuberculosis with Extensive Resistance to Second-Line Drugs Worldwide 2000-2004. Morbidity Mortality Wkly. Rep. 2006, 55, 301-305.
28. (c) XDR-TB - A Global Threat. Editorial. Lancet 2006, 368, 964.
29. (a) Coker, R. J. Multidrug-Resistant Tuberculosis: Public Health Challenges. Trop. Med. Int. Health 2004, 9, 25-40.
30. (b) Pozniak, A. Mycobacterial Diseases and HIV. J. HIV Ther. 2002, 7, 13-16.
31. Colditz, G. A.; Brewer, T. F.; Berkey, C. S.; Wilson, M. E.; Burdick, E.; Fineberg, H. V.; Mosteller, F. Efficacy of BCG Vaccine in the Prevention of Tuberculosis. Meta-Analysis of the Published Literature. JAMA, J. Am Med. Assoc. 1994, 271, 698-702.
32. (a) Koehler, C. S. W. Consumption the Great Killer. Modern Drug Discovery 2002, 47-49.
33. (b) Guerrero, A. Nosocomial Transmission of M. Bovis Resistant to 11 Drugs in People with Advanced HIV-1 Infection. Lancet 1997, 350, 1738-1742.
34. Rai, D.; Johar, M.; Manning, T.; Agrawal, B.; Kunimoto, D. Y.; Kumar, R. Design and Studies of Novel 5-Substituted Alkynyl Pyrimidine Nucleosides as Potent Inhibitors of Mycobacteria. J. Med. Chem. 2005, 48, 7012-7017.
35. Johar, M.; Manning, T.; Kunimoto, D. Y.; Kumar, R. Synthesis and in vitro Anti-Mycobacterial Activity of 5-Substituted Pyrimidine Nucleosides. Bioorg. Med Chem. 2005, 13, 6663-6671.
36. Kim, C. H.; Marquez, V. E.; Broder, S.; Mitsuya, H.; Driscoll, J. S. Potential Anti-AIDS Drags. 2′,3′-Dideoxycytidine Analogues. J. Med. Chem. 1987, 30, 862-866.
37. Lin, T. S.; Chen, M. S.; McLaren, C.; Gao, Y. S.; Ghazzouli, I.; Prusoff, W. H. Synthesis and Antiviral Activity of Various 3′-Azido, 3′-Amino, 2′,3′-Unsaturated, and 2′,3′-Dideoxy Analogues of Pyrimidine Deoxyribonucleosides against Retroviruses. J. Med. Chem. 1987, 30, 440-444.
38. Van Aerschot, A.; Everaert, D.; Balzarini, J.; Augustyns, K.; Jie, L.; Janssen, G.; Peeters, O.; Blaton, N.; De Ranter, C.; De Clercq, E. Synthesis and anti-HIV Evaluation of 2′,3′-Dideoxyribo-5-chloropyrimidine Analogues: Reduced Toxicity of 5-Chlorinated 2′,3′- Dideoxynucleosides. J. Med. Chem. 1990, 33, 1833-1839.
39. Balzarini, J.; Van Aerschot, A.; Pauwels, R.; Baba, M.; Schols, D.; Herdewijn, P.; De Clercq, E. 5-Halogeno-3′-fluoro-2′,3′- dideoxyuridines as Inhibitors of Human Immunodeficiency Virus (HIV): Potent and Selective Anti-HIV Activity of 3′-Fluoro-2′,3′-dideoxy-5- chlorouridine. Mol. Pharmacol. 1989, 35, 571-577.
40. Meier, C.; Knispel, T.; De Clercq, E.; Balzarini, J. CycloSal- pronucleotides of 2′,3′-Dideoxyadenosine and 2′,3′- Dideoxy-2′,3′-didehydroadenosine: Synthesis and Antiviral Evaluation of a Highly Efficient Nucleotide Delivery System. J. Med. Chem. 1999, 42, 1604-1614.
41. Murakami, K.; Shirasaka, T.; Yoshioka, H.; Kojima, E.; Aoki, S.; Ford, H.; Driscoll, J. S.; Kelley, J. A.; Mitsuya, H. E. coli Mediated Biosynthesis and in Vitro Anti-HIV Activity of Lipophilic 6-Halo-2′, 3′-dideoxypurine Nucleosides. J. Med. Chem. 1991, 34, 1606-1612.
42. Shirasaka, T.; Murakami, K.; Ford, H.; Kelley, J. A.; Yoshioka, H.; Kojima, E.; Aoki, S.; Broder, S.; Mitsuya, H. Lipophilic Halogenated Congeres of 2′,3′-Dideoxypurine Nucleosides Active against Human Immunodeficiency Virus in Vitro. Proc. Natl. Acad. Sci., U.S.A. 1990, 87, 9426-9430.
43. Robins, M. J.; Wilson, J. S.; Madej, D.; Low, N. H.; Hansske, F.; Wnuk, S. F. Nucleic Acid Related Compounds. 88. Efficient Conversions of Ribonucleosides into Their 2′,3′-Anhydro,2′(and 3′)-deoxy, 2′,3′-Didehydro-2′,3′-dideoxy, and 2′,3′-Dideoxynucleoside Analogs. J. Org. Chem. 1995, 60, 7902-7908.
44. 3 Adenosine Receptors. J. Med. Chem. 1995, 38, 1720-1735.
45. Krawczyk, S. H.; Renau, T. E.; Reza Nassiri, M.; Westreman, A. C.; Wotring, L. L.; Drach, J. C.; Townsend, L. B. Synthesis and Evaluation of Certain Thiosangivamycin Analogs as Potential Inhibitors of Cell Proliferation and Human Cytomegalovirus. J. Med. Chem. 1995, 38, 4115-4119.
46. Kojima, E.; Shirasaka, T.; Machida, M.; Yoshioka, H.; Murakami, K.; Mitsuya, H. Synthesis and Structure-Activity Relationships of 2′,3′-Dideoxypurine Nucleosides as Potential Antiretroviral Agents. Nucleic Acids Symp. Ser. 1991, 25, 91-92.
47. Ramasamy, K.; Imamura, M.; Hanna, N. B.; Finch, R. A.; Avery, T. L.; Robins, R. K.; Revankar, G. R. Synthesis and Antitumor Evaluation in Mice of Certain 7-Deazapurine (pyrrolo[2,3-d]pyrimidine) and 3-Deazapurine (imidazo[4,5-c]pyridine) Nucleosides Structurally Related to Sulfenosine, Sulfinosine, and Sulfonosine. J. Med. Chem. 1990, 33, 1220-1225.
48. (a) Franzblau, S. G.; Witzig, R. S.; McLaughlin, J. C.; Torres, P.; Madico, G.; Hernandez, A.; Degnan, M. T.; Cook, M. B.; Quenzer, V. K.; Ferguson, R. M.; Gilman, R. H. Rapid, Low-Technology MIC Determination with Clinical Mycobacterium tuberculosis Isolates by Using the Microplate Alamar Blue Assay. J. Clin. Microbiol. 1998, 36, 362-366.
49. (b) Collins, L.; Franzblau, S. G. Microplate Alamar Blue Assay versus BACTEC 460 System for High-Throughput Screening of Compounds against Mycobacterium tuberculosis and Mycobacterium avium. Antimicrob. Agents. Chemother. 1997, 41, 1004-1009.
50. (c) Bermudez, L. E.; Inderlied, C. B.; Kolonoski, P.; Wu, M.; Aralar, P.; Young, L. S. Telithromycin Is Active against Mycobacterium avium in Mice Despite Lacking Significant Activity in Standard in Vitro and Macrophage Assays and Is Associated with Low Frequency of Resistance during Treatment. Antimicrob. Agents Chemother. 2001, 45, 2210-2214.
51. Ryan, A. J.; Gray, N. M.; Lowe, P. N.; Chung, C. Effect of Detergent on Promiscuous Inhibitors. J. Med. Chem. 2003, 46, 3448-3451.
52. Neugebauer, J. M. Detergents: An Overview. Methods Enzymol. 1990, 182, 239-153.
53. Cole, S. T.; Brosch, R.; Parkhill, J.; Garnier, T.; Churcher, C.; Harris, D.; Gordon, S. V.; Eiglmeier, K.; Gas, S.; Barry, C. E., III; Tekala, F.; Badcock, K.; Bashman, D.; Brown, D.; Chillingworth, T. R.; Connor, R.; et al. Deciphering the Biology of Mycobacterium tuberculosis from the Complete Genome Sequence. Nature 1998, 393, 537-544.
54. Herdewijn, P.; Van Aerschot, A.; Kerremans, L. Syntheis of Nucleosides Fluorinated in the Sugar Moiety: The Application of Diethylaminosulfurtrifluoride to the Synthesis of Fluorinated Nucleosides. Nucleosides Nucleotides 1989, 8, 65-96.